These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 15591148)

  • 1. Inhibition of the vascular endothelial cell (VE)-specific adhesion molecule VE-cadherin blocks gonadotropin-dependent folliculogenesis and corpus luteum formation and angiogenesis.
    Nakhuda GS; Zimmermann RC; Bohlen P; Liao F; Sauer MV; Kitajewski J
    Endocrinology; 2005 Mar; 146(3):1053-9. PubMed ID: 15591148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The vascular endothelial growth factor (VEGF)/VEGF receptor 2 pathway is critical for blood vessel survival in corpora lutea of pregnancy in the rodent.
    Pauli SA; Tang H; Wang J; Bohlen P; Posser R; Hartman T; Sauer MV; Kitajewski J; Zimmermann RC
    Endocrinology; 2005 Mar; 146(3):1301-11. PubMed ID: 15591152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preovulatory treatment of mice with anti-VEGF receptor 2 antibody inhibits angiogenesis in corpora lutea.
    Zimmermann RC; Hartman T; Bohlen P; Sauer MV; Kitajewski J
    Microvasc Res; 2001 Jul; 62(1):15-25. PubMed ID: 11421657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability.
    Liao F; Doody JF; Overholser J; Finnerty B; Bassi R; Wu Y; Dejana E; Kussie P; Bohlen P; Hicklin DJ
    Cancer Res; 2002 May; 62(9):2567-75. PubMed ID: 11980651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
    Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
    Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Green tea catechins inhibit VEGF-induced angiogenesis in vitro through suppression of VE-cadherin phosphorylation and inactivation of Akt molecule.
    Tang FY; Nguyen N; Meydani M
    Int J Cancer; 2003 Oct; 106(6):871-8. PubMed ID: 12918064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The vascular endothelial growth factor/fms-like tyrosine kinase system in human ovary during the menstrual cycle and early pregnancy.
    Otani N; Minami S; Yamoto M; Shikone T; Otani H; Nishiyama R; Otani T; Nakano R
    J Clin Endocrinol Metab; 1999 Oct; 84(10):3845-51. PubMed ID: 10523040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome.
    Scotti L; Irusta G; Abramovich D; Tesone M; Parborell F
    Mol Cell Endocrinol; 2011 Mar; 335(2):116-25. PubMed ID: 21238536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of differential VE-cadherin dynamics in cell rearrangement during angiogenesis.
    Bentley K; Franco CA; Philippides A; Blanco R; Dierkes M; Gebala V; Stanchi F; Jones M; Aspalter IM; Cagna G; Weström S; Claesson-Welsh L; Vestweber D; Gerhardt H
    Nat Cell Biol; 2014 Apr; 16(4):309-21. PubMed ID: 24658686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of vascular endothelial growth factor in the primate ovary up-regulates hypoxia-inducible factor-1alpha in the follicle and corpus luteum.
    Duncan WC; van den Driesche S; Fraser HM
    Endocrinology; 2008 Jul; 149(7):3313-20. PubMed ID: 18388198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of vascular endothelial growth factor in ovarian physiology - an overview.
    Kaczmarek MM; Schams D; Ziecik AJ
    Reprod Biol; 2005 Jul; 5(2):111-36. PubMed ID: 16100562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a transiently exposed VE-cadherin epitope that allows for specific targeting of an antibody to the tumor neovasculature.
    May C; Doody JF; Abdullah R; Balderes P; Xu X; Chen CP; Zhu Z; Shapiro L; Kussie P; Hicklin DJ; Liao F; Bohlen P
    Blood; 2005 Jun; 105(11):4337-44. PubMed ID: 15701713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation.
    Lin MT; Yen ML; Lin CY; Kuo ML
    Mol Pharmacol; 2003 Nov; 64(5):1029-36. PubMed ID: 14573751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Messenger ribonucleic acids for MAC25 and connective tissue growth factor (CTGF) are inversely regulated during folliculogenesis and early luteogenesis.
    Wandji SA; Gadsby JE; Barber JA; Hammond JM
    Endocrinology; 2000 Jul; 141(7):2648-57. PubMed ID: 10875270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human chorionic gonadotropin controls luteal vascular permeability via vascular endothelial growth factor by down-regulation of a cascade of adhesion proteins.
    Herr D; Fraser HM; Konrad R; Holzheu I; Kreienberg R; Wulff C
    Fertil Steril; 2013 May; 99(6):1749-58. PubMed ID: 23465821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model.
    Gomez R; Gonzalez-Izquierdo M; Zimmermann RC; Novella-Maestre E; Alonso-Muriel I; Sanchez-Criado J; Remohi J; Simon C; Pellicer A
    Endocrinology; 2006 Nov; 147(11):5400-11. PubMed ID: 16901966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor receptor 2-mediated angiogenesis is essential for gonadotropin-dependent follicle development.
    Zimmermann RC; Hartman T; Kavic S; Pauli SA; Bohlen P; Sauer MV; Kitajewski J
    J Clin Invest; 2003 Sep; 112(5):659-69. PubMed ID: 12952915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibody to vascular endothelial-cadherin is a potent inhibitor of angiogenesis, tumor growth, and metastasis.
    Liao F; Li Y; O'Connor W; Zanetta L; Bassi R; Santiago A; Overholser J; Hooper A; Mignatti P; Dejana E; Hicklin DJ; Bohlen P
    Cancer Res; 2000 Dec; 60(24):6805-10. PubMed ID: 11156369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IQGAP1 mediates VE-cadherin-based cell-cell contacts and VEGF signaling at adherence junctions linked to angiogenesis.
    Yamaoka-Tojo M; Tojo T; Kim HW; Hilenski L; Patrushev NA; Zhang L; Fukai T; Ushio-Fukai M
    Arterioscler Thromb Vasc Biol; 2006 Sep; 26(9):1991-7. PubMed ID: 16763158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial-cadherin tyrosine phosphorylation in angiogenic and quiescent adult tissues.
    Lambeng N; Wallez Y; Rampon C; Cand F; Christé G; Gulino-Debrac D; Vilgrain I; Huber P
    Circ Res; 2005 Feb; 96(3):384-91. PubMed ID: 15662029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.